RT Journal Article
SR Electronic
T1 Propranolol for infantile haemangiomas: a review
JF Archives of Disease in Childhood
JO Arch Dis Child
FD BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health
SP 890
OP 893
DO 10.1136/adc.2010.208884
VO 96
IS 9
A1 Starkey, E
A1 Shahidullah, H
YR 2011
UL http://adc.bmj.com/content/96/9/890.abstract
AB Infantile haemangiomas are the most common benign tumour of infancy. However the majority are self-resolving and only a small minority of cases require treatment, with various different medications being used in the past. Over the last few years, propranolol, a non-selective β-blocker, has become a popular and successful treatment for infantile haemangiomas. However, further research on its safety is needed if it is going to be used more frequently. This article summarises the current literature on propranolol for haemangioma treatment with emphasis on its toxicity and adverse event profile.